[Avian Escherichia coli virulence factors associated with coli septicemia in broiler chickens]. / Factores de virulencia de Escherichia coli aviar asociados a la colisepticemia en pollos de engorde.

In order to detect phenotypic characteristics associated with pathogenicity, 25 strains of Escherichia coli, isolated from clinical cases of colisepticemia in broiler chickens, were examined to determine the following properties: colicinogenicity, colicin V production, type 1 fimbriae, hemolysin expression and motility. Colicinogenicity occurred in 72% of the strains, 56% of all strains produced colicin V, 84% were positive for type 1 fimbriae and 80% were positive for motility. None of the strains had hemolytic activity; however, all of them, expressed at least one of the other characteristics studied. These results suggest that the diversity of phenotypes detected partially explain the multifactorial nature of avian colisepticemia.

Factores de virulencia de Escherichia coli aviar asociados a la colisepticemia en pollos de engorde / Avian Escherichia coli virulence factors associated with coli septicemia in broiler chickens

In order to detect phenotypic characteristics associated with pathogenicity, 25 strains of Escherichia coli, isolated from clinical cases of colisepticemia in broiler chickens, were examined to determine the following properties: colicinogenicity, colicin V production, type 1 fimbriae, hemolysin expression and motility. Colicinogenicity occurred in 72 of the strains, 56 of all strains produced colicin V, 84 were positive for type 1 fimbriae and 80 were positive for motility. None of the strains had hemolytic activity; however, all of them, expressed at least one of the other characteristics studied. These results suggest that the diversity of phenotypes detected partially explain the multifactorial nature of avian colisepticemia.(AU)

Factores de virulencia de Escherichia coli aviar asociados a la colisepticemia en pollos de engorde / Avian Escherichia coli virulence factors associated with coli septicemia in broiler chickens

In order to detect phenotypic characteristics associated with pathogenicity, 25 strains of Escherichia coli, isolated from clinical cases of colisepticemia in broiler chickens, were examined to determine the following properties: colicinogenicity, colicin V production, type 1 fimbriae, hemolysin expression and motility. Colicinogenicity occurred in 72 of the strains, 56 of all strains produced colicin V, 84 were positive for type 1 fimbriae and 80 were positive for motility. None of the strains had hemolytic activity; however, all of them, expressed at least one of the other characteristics studied. These results suggest that the diversity of phenotypes detected partially explain the multifactorial nature of avian colisepticemia.

Factores de virulencia de Escherichia coli aviar asociados a la colisepticemia en pollos de engorde. / [Avian Escherichia coli virulence factors associated with coli septicemia in broiler chickens]

In order to detect phenotypic characteristics associated with pathogenicity, 25 strains of Escherichia coli, isolated from clinical cases of colisepticemia in broiler chickens, were examined to determine the following properties: colicinogenicity, colicin V production, type 1 fimbriae, hemolysin expression and motility. Colicinogenicity occurred in 72

of the strains, 56

of all strains produced colicin V, 84

were positive for type 1 fimbriae and 80

were positive for motility. None of the strains had hemolytic activity; however, all of them, expressed at least one of the other characteristics studied. These results suggest that the diversity of phenotypes detected partially explain the multifactorial nature of avian colisepticemia.

The expression and localization of Scl-70/DNA topoisomerase I vary throughout the cell cycle.

PURPOSE AND METHODS: We investigated the expression and localization of topoisomerase I by Western blot and indirect fluorescent antibody assay, respectively, using anti-Scl-70/topo I from patients with diffuse scleroderma. The contribution of topoisomerase I to DNA replication was assessed using cells treated with the topoisomerase I inhibitor camptothecin. RESULTS: Scl-topo I was detected at all cell cycle phases as a single immunoreactive band of 100 kDa. Extracts from cells in the S phase contained the largest amount of immunoreactive Scl-70/topo I. Variations in the subcellular distribution of Scl-70/topo I were seen throughout the cell cycle, with a speckled nucleoplasmic distribution during G1 contrasting with concentration within the nucleolus during S. Camptothecin exposure blocked topoisomerase I expression and caused a significant decrease in DNA production. CONCLUSION: These data suggest (1) that topomerase I is active mainly during the S phase and contributes to DNA replication, and (2) that topoisomerase I may be involved in ribosomal gene transcription.

[Effectiveness and safety of lansoprazole in the treatment of peptic ulcer]. / Efectividad y seguridad del lansoprazol en el tratamiento de la úlcera péptica.

BACKGROUND: Lansoprazole, a new proton pump inhibitor, is now available in Mexico. It has been tested elsewhere with excellent results. AIM: To study its safety and efficacy in Mexican patients. METHOD: 40 patients with gastric or duodenal ulcer larger than 0.5 cm, from 4 hospitals in central Mexico, were included. All were subjected to a complete medical history and upper GI endoscopy. symptoms (epigastric pain, heartburn, regurgitation, nausea, vomiting) were graded 1 to 4 according to severity. Lansoprazole (one 30 mg capsule/ day) was prescribed for 4 weeks in duodenal ulcer 8 weeks in gastric ulcer. Each patient was seen once a week at the office for compliance, symptom evaluation and side effects. A second endoscopy was performed at the end of the respective treatment period. Blood (CBC, chemistries) and urine tests were performed at the beginning and end of the study. RESULTS: 23 men and 17 women were included, Mean age: 53.8 yr. (19-95). 11 gastric ulcers and 29 duodenal ulcers. 27 measured 0.6-1.5 cm; 6 ulcers measured 1.6-2.5 cm; 6 ulcers were larger than 2.5 cm. 8 patients were bleeding at admission and 4 had multiple ulcers. 2 patients were lost to follow up. symptom grading: 18 patients had 10 points or less, 21 had more than 10 points, one bleeding patient was otherwise asymptomatic. After the first week of treatment, 42% were asymptomatic, after the 2nd. week, 75% were asymptomatic and 95% at the end of the study. The second endoscopy documented complete ulcer healing in 92% out of 37 remaining patients; further lansoprazole treatment healed 2 out of three unhealed ulcers. One patient underwent surgery for duodenal bulb stenosis. Side effects were reported by 2 patients. Treatment had to be discontinued in one patient because of headache. There was no effect of lansoprazole over the laboratory tests. CONCLUSIONS: Lansoprazole was effective for prompt symptom relief in most patients and was able to heal more than 90% of gastric and duodenal ulcers with minimal side effects.

Phosphorylation profiles of 60 kD Ro antigen in synchronized HEp-2 cells.

The purpose of this study was to determine whether phosphorylation has an effect on the characteristics of the 60 kD Ro antigen throughout the cell cycle. Cell extracts of synchronized HEp-2 cells were phosphorylated in vitro with exogenous ATP, examined by SDS-PAGE and Western blot, and probed with specific anti-Ro sera. In addition, cellular ATP pools were radiolabelled in vivo with 32P. The presence of the Ro protein was detected with a molecular weight of 60 kD during all phases of the cell cycle, except at the M phase, where it was increased to 65 kD. Phosphorylation of the in vitro and in vivo cell extracts increased the molecular mass to 65 kD. Moreover immunoprecipitation assays demonstrated that Ro is hyperphosphorylated in the M phase. Phosphorylation did not change the recognition pattern of the anti-Ro sera.

[A 10-year prolective study on cancer of the digestive system]. / Estudio prolectivo de 10 años de cáncer del aparato digestivo.

OBJECTIVE: A ten year prolective and multicentre study of cancer of the Digestive Tract aims to evaluate the variations on frequency and to identify risk factors. METHODS: Ten hospitals are participating five in Mexico City and five in other states. Data were obtained through the hospitals files and specially designed questionnaires, the latter mainly diet and habits oriented. RESULTS: Through this ten years in the 4,715 cases studied we can appreciate a decreasing tendency of the carcinoma of the stomach (GC) that has been the most frequent until 1984 in the general group General Hospital and Instituto Nacional de la Nutrición. Since then and up to date, first place in frequency in shared between the stomach and colorectal carcinoma (CRC). CRC has been increasing even in the General Hospital in which GC was very high. Eighth years ago we found that people in those hospitals in which GC was high the diet was poor in proteins, fat A and C vitamin. People in those hospitals with high frequency of CRC had diet high in protein, fat and low in fiber. A new study on diet is ongoing. Gallbladder and biliary tract carcinoma has been increasing in all the hospitals. A high O blood group was found in the Juarez Hospital in which gallbladder carcinoma was the highest. O group is highest in the indian people. Cancer of the gallbladder is very high in Pimas and Navajos indians. A plan to study litogenic index and culture of salmonella is going to be practiced in bile from normal and gallbladder carcinoma. Concerning habits, tobacco and alcohol consumption are most frequent in cancer of the esophagus and pancreas. Also coffee consumption is high in the latter. CONCLUSIONS: Along this 10-year study, the frequency of gastric cancer has been decreasing. Instead, the frequencies of colo rectal and biliary tract cancers have been increasing. Variations in frequencies correlated with the composition of the diet, fiber consumption habits and racial characteristics of the different groups.

[Sodium benzoate in portal-systemic-encephalopathy-induced blood ammonia normalization and clinical improvement. Interim report of a double-blind multicenter trial]. / Derivación metabólica del amonio plasmático con benzoato de sodio, como método de tratamiento en pacientes con cirrosis y encefalopatía portosistémica. Informe interino de un estudio multicéntrico, doble ciego.

To investigate the therapeutic efficacy of sodium benzoate (SB) in a cirrotic population with chronic portal systemic encepalopathy (PSE), we performed a double blind, randomised, multicentric, clinical trial, comparing SB versus a standard therapy of lactitol (LA). To perform the study blind, syrups containing the two drugs were prepared. To date 27 patients have been studied. Of these, 12 received SB (5.6 g/day) and 15 received LA (29 g/day). Standard PSE parameters were assessed and hippurate urinary excretion was measured before and after the trial. For the SB group, basal and final PSE index were 0.39 +/- 0.16 and 0.17 +/- 0.1 respectively (p < 0.001). The Group on LA had a PSE index of 0.40 + 0.1 and 0.23 +/- 0.18 (basal and final respectively) (p < 0.001). The final hippurate excretion for SB group was 2498.9 mg/24 h. The hippurate excretion for the LA group suffer no changes (traces). No serious side effects were observed with either therapy. We suggested that SB is a safe, efficacious and comfortable alternate treatment for PSE.

[Prophylactic effect of Misoprostol on gastric lesions induced by aspirin (ASA) in healthy subjects]. / Efecto profiláctico de Misoprostol sobre las lesiones gástricas inducidas por aspirina (AAS) en sujetos sanos.

Aspirin (ASA) and other nonsteroidal anti-inflammatory drugs (NSAIDs), are extensively used for treating rheumatic diseases, inflammatory problems, and pain of different etiologies. However, their use is limited by the damage they may produce to the gastroduodenal mucosa. The purpose of this double-blind, multicenter, randomized, placebo-controlled study was to assess and corroborate the protective effect of misoprostol on the gastric mucosa against ASA injury. Following endoscopic screening, 60 healthy male and female subjects were assigned, at random, to one of two treatment groups. One group was treated with ASA (3.0 g/day, in three divided doses) and misoprostol (600 mcg/day, co-administered with ASA); the other with ASA and placebo. After six days of treatment, endoscopy was repeated and the gastric mucosa was graded on a 5 point endoscopic score. Protection was defined as mucosa having an endoscopic score of 2 or less (10 or fewer hemorrhages or erosions). Misoprostol produced a significant (p = 0.005) and profound protection of the gastric mucosa against ASA injury and was well tolerated. These results suggest that misoprostol should have significant therapeutic utility in the treatment and prevention of gastropathy due to NSAIDs.